IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

Status Completed

Clinical Trial Summary

The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.

Clinical Trial Description

The ultimate goal of this pilot project is to generate proof-of-concept data showing that treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients. This project has relevant clinical implications due to the severe side effects of and lack of response to current therapies.

From the review of literature, it can be postulated that:

1. the beneficial effects of IVIg for patients with CLE should be prompt, with marked improvement within a few weeks;

2. clinical improvement should last several weeks after the last infusion; and

3. remission may be prolonged by maintenance IVIg therapy.

Although this is only a non-controlled study, the investigator expects that IVIg will improve CLE, including those resistant to standard treatments. It is anticipated that treatment with IVIg will facilitate healing of extensive cutaneous lesions and achieve rapid remission. Maintenance therapy with repeated monthly pulses of IVIg is expected to keep the disease in remission during the treatment-free follow up observational period. The results will provide the basis a multicenter randomized controlled study to identify which CLE subsets will benefit the most and which protocol will provide the optimal clinical outcome. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01841619
Study type	Interventional
Source	University of California, Irvine
Contact
Status	Completed
Phase	Phase 0
Start date	March 2013
Completion date	November 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01776190` - Low-dose UVA1 Radiation in Cutaneous Lupus Patients	N/A
Completed	`NCT00420173` - Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)	N/A
Terminated	`NCT04809623` - Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)	Phase 1
Completed	`NCT01300208` - To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus	Phase 2
Terminated	`NCT01470313` - A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus	Phase 1
Completed	`NCT01146444` - Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)	N/A
Not yet recruiting	`NCT06015737` - A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Phase 3
Completed	`NCT03134222` - Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)	Phase 2
Completed	`NCT01629784` - Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus	N/A
Completed	`NCT00470912` - Sunscreen RV 2457C in Photoinduced CLE	Phase 3
Completed	`NCT00523588` - Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser	Phase 2
Terminated	`NCT01498406` - Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus	Phase 2
Completed	`NCT04647708` - Study of M5049 in CLE and SLE Participants	Phase 1
Completed	`NCT03817424` - A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis	Phase 1
Active, not recruiting	`NCT03260166` - Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus	Phase 2
Completed	`NCT00317681` - Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)	Phase 2
Completed	`NCT04781816` - Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus	Phase 2